Bio-Techne Corporation recently reported past second-quarter and six-month results to December 31, 2025, with sales essentially flat year-on-year at about US$295.88 million for the quarter and US$582.

Bio-Techne Corporation (NASDAQ:TECH) Q2 2026 Earnings Call Transcript February 4, 2026 Bio-Techne Corporation beats earnings ...

Q2 2026 Management View CEO Kim Kelderman reported that "our second quarter performance was largely in line with our expectations. Continued strength from our large pharma customers was offset by a ...

Earlier in 2026, Bio-Techne highlighted its leadership in spatial biology and proteomic analysis under new CEO Kim Kelderman, ...

Bio-Techne (NASDAQ: TECH) just disclosed its Q2 earnings on Wednesday, February 4, 2026 at 06:30 AM. Here's a brief overview ...

Shares of Bio-Techne Corp. TECH slid 4.09% to $65.86 Thursday, on what proved to be an all-around grim trading session for ...

ClearBridge Investments, an investment management company, released its “ClearBridge Mid Cap Strategy” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. In an ...

Bio-Techne Corp. closed 11.77% below its 52-week high of $75.69, which the company achieved on February 7th.

Combines chemiluminescence detection with dual-channel fluorescence in the near-infrared and infrared (NIR and IR) ranges for expanded multiplexing Enables up to 24 targets per sample and supports ...

RBC Capital on Tuesday upgraded Bio-Techne Corporation (NASDAQ:TECH), noting that recent end-market weakness has over-penalized one of the best assets in the life science and tools (LST) sector, ...

The company's 10-Ks for fiscal year 2025 identify certain factors that could cause the company's actual results to differ ...

Q2 2026 Earnings Call February 4, 2026 9:00 AM ESTCompany ParticipantsDavid Clair - VP of Investor Relations & ...